

**Alessandra Michelucci**

Indirizzo di domicilio: Via Mercanti 33, Pisa (56127) – Italia

Indirizzo di residenza: Via Carducci 72, Massa (54100) – Italia

Telefono personale: +39 3289430138

Email personale: alessandra.michelucci@gmail.com

Numero di iscrizione all'Albo dei Medici: n. 02029 (Massa)

**INFORMAZIONI PERSONALI**

**Data di nascita:** 06 aprile 1994
**Luogo di nascita:** Massa (MS), Italia
**Sesso:** Femminile
**Nazionalità:** Italiana
**Codice Fiscale:** MCHLSN94D46F023J

### **FORMAZIONE E ISTRUZIONE**

**Dal 2023 - in corso:** Dottoranda in “Health Science, Technology and Management”, Università Sant'Anna, Pisa (Italia). 10 borse di studio internazionali disponibili.

**2020 – 2025:** Specializzazione in Dermatologia e Venereologia, Università di Siena, Siena (Italia). Laurea conseguita il 27/01/2025. Voto finale: 70/70 con lode**.**

**2014 – 2019:** Laurea in Medicina e Chirurgia, Dipartimento di Medicina Clinica e Sperimentale, Università di Pisa, Pisa (Italia). Laurea conseguita il 19/07/2019.Voto finale 110/110 con lode e dignità di stampa.

**2008 – 2013:** Diploma di Maturità Classica, Liceo Classico Pellegrino Rossi, Massa (Italia). Voto finale: 100/100 con lode.

**ASSOCIAZIONI SCIENTIFICHE**

* SIDeMaST - Società Italiana Dermatologia e Malattie Sessualmente Trasmesse, Italy
* SIRTES - International School of Tissue Repair, Italy
* ISCU - International Society of Cutaneous Ultrasound, Italy
* EADV – European Academy of Dermatology and Venereology

**PREMI E RICONOSCIMENTI**

* **Premio per la Miglior Presentazione Poster**, Convegno Nazionale BiGeneration, Roma, 29-30 novembre 2023.
* **Premio per la Migliore Presentazione Poster**, Symposium on Advanced Wound Care (SAWC) Spring National Harbor, 26-30 aprile 2023.
* **Vincitrice di Borsa di Studio**, 25th World Congress of Dermatology, Singapore, 3-8 luglio 2023.
* **Young Investigator Award**, European Hidradenitis Suppurativa Foundation (EHSF) annual meeting, Firenze, 8-10 febbraio 2023.

**PUBBLICAZIONI (ARTICOLI E ABSTRACTS) E CAPITOLI DI LIBRI**

* **Michelucci A**, Fidanzi C, Manzo Margiotta F, et al. Presurgical Mapping With Ultra-high Frequency Ultrasound of Hidradenitis Suppurativa Lesions Treated With Wide Local Excision and Secondary Intention Healing. *Dermatol Surg*. 2025;51(1):36-39. doi:10.1097/DSS.0000000000004349
* Manzo Margiotta F, Fidanzi C, Pardossi S, et al. Correlation between skin cancer and therapy with anti-IL monoclonal antibodies in patients affected by moderate-to-severe psoriasis: an observational monocentric study. *Eur J Cancer Prev*. Published online January 7, 2025. doi:10.1097/CEJ.0000000000000948
* **Michelucci A**, Granieri G, Cei B, et al. Enhancing Hidradenitis Suppurativa Assessment: The Role of Ultra-High Frequency Ultrasound in Detecting Microtunnels and Refining Disease Staging. *J Ultrasound Med*. Published online December 21, 2024. doi:10.1002/jum.16635
* Janowska A, Fidanzi C, Romanelli M, **Michelucci A**, Bevilacqua M, Dini V. Ultra-high-frequency Ultrasound in the Objective Assessment of Chlormethine Gel Efficacy: A Case Report. *Acta Dermatovenerol Croat*. 2024;32(2):105-108.
* Magnano M, Rossari S, Trovato T, et al. Risankizumab in Oncologic Patients With Psoriasis: A Case Series. *JEADV Clinical Practice*. Dec, 2024.
* **Michelucci A**, Margiotta FM, Salvia G, et al. Effectiveness of wide local excision and secondary intention healing in Hidradenitis Suppurativa: a single-center study on quality of life and mental health outcomes. *Clin Exp Dermatol*. Published online November 21, 2024. doi:10.1093/ced/llae515
* Lorenzoni E, DI Cesare A, Rosi E, et al. Risankizumab in very elderly patients in real-world practice. *Ital J Dermatol Venerol*. Published online November 7, 2024. doi:10.23736/S2784-8671.24.07941-6
* Sechi A, Caposiena Caro RD, **Michelucci A**, et al. CO2 Laser Versus Surgical Deroofing for the Treatment of Hidradenitis Suppurativa Tunnels: A Comparative Multicentric, Retrospective Study. *Dermatol Surg*. Published online November 19, 2024. doi:10.1097/DSS.0000000000004498
* Megna M, Orsini D, Assorgi C, et al. The Risk of Candidiasis During Treatment with Bimekizumab for the Management of Plaque Psoriasis: A 16-Week Multicenter Real-World Experience - IL PSO (Italian Landscape Psoriasis). *Clin Exp Dermatol*. Published online October 7, 2024. doi:10.1093/ced/llae400
* Manzo Margiotta F, Gambino G, Pratesi F, **Michelucci A**, Pisani F, Rossi L, Dini V, Romanelli M, Migliorini P. Interleukin-1 family cytokines and soluble receptors in hidradenitis suppurativa. Experimental dermatology. 2024; 33(9), e15179. doi:10.1111/exd.15179
* Dini V, **Michelucci A**, Granieri G, Zerbinati N, Margiotta FM, Romanelli M. Evaluation of post-surgical complications of hidradenitis suppurativa lesions explored with presurgical ultra-high frequency ultrasound mapping. J Wound Care. 2024;33(Sup8):S10-S16. doi:10.12968/jowc.2023.0224
* **Michelucci A**, Manzo Margiotta F, Innocenti S, et al. Wound area severity index (WASI): A novel tool for assessing and predicting healing times in hidradenitis suppurativa postsurgical wounds. Exp Dermatol. 2024;33(8):e15149. doi:10.1111/exd.15149
* **Michelucci A**, Margiotta FM, Cartocci A, et al. Long-term drug survival of risankizumab in psoriasis: insights from a real-life multicenter study on hard-to treat areas. Arch Dermatol Res. 2024;316(6):272. Published 2024 May 25. doi:10.1007/s00403-024-03146-2
* Salvia G, Bevilacqua M, Manzo Margiotta F, **Michelucci A**, Granieri G, Fidanzi C, Dini V, Romanelli M, Mazzatenta C. Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum. The Australasian journal of dermatology, 65(4), e111 e113. Published 2024 Jun doi: 10.1111/ajd.14266
* Manzo Margiotta F, **Michelucci A**, Fidanzi C, et al. Monoclonal Antibodies in the Management of Inflammation in Wound Healing: An Updated Literature Review. J Clin Med. 2024;13(14):4089. Published 2024 Jul 12. doi:10.3390/jcm13144089
* **Michelucci A**, Manzo Margiotta F, Granieri G, et al. Risankizumab as a Therapeutic Approach for Recalcitrant Pyoderma Gangrenosum. Adv Skin Wound Care. 2024;37(5):276-279. doi:10.1097/ASW.0000000000000129
* **Michelucci A**, Romanelli P, Dini V, Romanelli M. Ulcers Caused by Calciphylaxis. In: Khanna, A.K., Tiwary, S.K. (eds) Uncommon Ulcers of the Extremities. Springer, Singapore (pp.85-100), Sep 2023. <https://doi.org/10.1007/978-981-99-1782-2_8>
* **Michelucci A**, Fidanzi C, Manzo Margiotta F, Ciccarese G, Panduri S, Iannone M, Romanelli M, Dini V. Paradoxical Eczematous Eruptions in patients with psoriasis treated with biological therapy. Dermatitis. Published online March 14, 2024. doi:10.1089/derm.2023.0315
* Manzo Margiotta F, **Michelucci A**, Capalbo E, et al. Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation. Ital J Dermatol Venerol. Published online November 23, 2023. doi:10.23736/S2784-8671.23.07648-X
* **Michelucci A**, Salvia G, Janowska A, et al. Fluorescence-Based Evaluation of Bacterial Load in Perilesional Skin: A Comparison Between Short Stretch Bandage and Zinc Oxide Bandage. Int J Low Extrem Wounds. Published online October 16, 2023. doi:10.1177/15347346231206449
* **Michelucci A**, Manzo Margiotta F, Granieri G, Dini V, Romanelli M. Post surgical complications of hidradenitis suppurativa lesions treated with a novel multistep approach: a monocentric, retrospective study. *Abstract*, EADV- Berlin 2023 Oct 11-14
* **Michelucci A**, Salvia G, Granieri G, Manzo Margiotta F, Panduri S, Dini V, Romanelli M. Ultra high frequency ultrasound imaging for the objective evaluation of nail psoriasis in patients treated with monoclonal antibodies. *Abstract*, EADV- Berlin 2023 Oct 11-14
* **Michelucci A,** Janowska A, Granieri G, et al. Advanced wound management approaches in Hidradenitis Suppurativa postsurgical lesions. Health Sci Rep. 2023;6(10):e1582. Published 2023 Oct 9. doi:10.1002/hsr2.1582
* Margiotta FM, **Michelucci A,** Panduri S, Angeloni L, Fidanzi C, Granieri G, et al. Bio-experienced psoriasis patients treated with anti-interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: results from a cohort of 305 patients. JEADV Clin Pract. 2023; 1–11. https://doi.org/10.1002/jvc2.236
* **Michelucci A**, Dini V, Salvia G, et al. Assessment and Monitoring of Nail Psoriasis with Ultra-High Frequency Ultrasound: Preliminary Results. Diagnostics (Basel). 2023;13(16):2716. Published 2023 Aug 21. doi:10.3390/diagnostics13162716
* Granieri G, **Michelucci A**, Manzo Margiotta F, et al. The Role of Ultra-High-Frequency Ultrasound in Pyoderma Gangrenosum: New Insights in Pathophysiology and Diagnosis. Diagnostics (Basel). 2023;13(17):2802. Published 2023 Aug 30. doi:10.3390/diagnostics13172802
* Dini V, Iannone M, **Michelucci A**, et al. Ultra-High Frequency UltraSound (UHFUS) Assessment of Barrier Function in Moderate-to-Severe Atopic Dermatitis during Dupilumab Treatment. Diagnostics (Basel). 2023;13(17):2721. Published 2023 Aug 22. doi:10.3390/diagnostics13172721
* Salvia G, Zerbinati N, Manzo Margiotta F, **Michelucci A**, et al. Ultra-High-Frequency Ultrasound as an Innovative Imaging Evaluation of Hyaluronic Acid Filler in Nasolabial Folds. Diagnostics (Basel). 2023;13(17):2761. Published 2023 Aug 25. doi:10.3390/diagnostics13172761
* Manzo Margiotta F, **Michelucci A**, Granieri G, Dini V, Romanelli M. Role of pre-surgical mapping with ultra-high frequency ultrasound of Hidradenitis Suppurativa lesions treated with wide local excision and second intention healing. *Abstract,* 25 th World Congress of Dermatology (WCD) – Singapore, 2023, July 3-8
* **Michelucci A**, Granieri G, Dini V, Romanelli M. Etiology, Classification and Advocating for a Holistic, Multidisciplinary Approach. Jan 2024. In: Pearls and Pitfalls in Skin Ulcer Management. Springer, Cham. pp 11–19. doi:10.1007/978-3-031-45453-0\_2
* Dini V, Granieri G, **Michelucci A**, Romanelli M. Wound Measurement is an Essential Part of Wound Management pp. 263-284 In: Chronic Wound Management: The Significance of Evidence and Technology, ed. R.Mani - Springer, 2023.
* Risanzikumab as a therapeutic choice for the management of difficult-to-treat cases of pyoderma gangrenosum. **Michelucci A**. *Abstract*, EWMA – Milan, 2023 May 3-5
* **Michelucci A**, Manzo Margiotta F, Salvia G, Granieri G, Fidanzi C, Bevilacqua M, Janowska A, Romanelli M. Fluorescence-based evaluation of bacterial load in chronic wounds and perilesional skin: a comparison between compressive multilayer bandage and zinc oxide bandage. *Abstract*, EWMA – Milan, 2023 May 3-5
* **Michelucci A**, Manzo Margiotta M, Salvia G, Granieri G, Janowska A, Romanelli M. Ph changes in chronic wounds treated with a cotton and polyamide elastic bandaged based on an oxygen-enriched oleic matrix. *Abstract*, EWMA – Milan, 2023 May 3-5
* Janowska A, Dini V, **Michelucci A**, Granieri G, Romanelli M. Fractional epidermal skin grafts in hard to heal wounds. *Abstract*, EWMA – Milan, 2023 May 3-5
* Manzo Margiotta M, **Michelucci A**, Salvia G, Granieri G, Janowska A, Romanelli M. Hidradenitis suppurativa post surgical lesions treated with a new ultraportable negative pressure wound therapy: a case report. *Abstract*, EWMA – Milan, 2023 May 3-5
* Salvia G, **Michelucci A**, Manzo Margiotta F, Granieri G, Janowska A, Romanelli M. Post surgical wounds treated with an oxygen-enriched oil-based medical device with prolonged release of reactive oxygen species. *Abstract*, EWMA – Milan, 2023 May 3-5
* Dragotto M, Capalbo E, Cartocci A, Manzo Margiotta F, **Michelucci A**, Rosi E, Ricceri F, Simoni B, Savarese I, Milanesi N, Rossari S, Magnano M, Romanelli M, Rubegni P, Prignano F, Di Cesare A, Panduri S, Pescitelli L, Trovato E. Real-life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study. J Eur Acad Dermatol Venereol. 2023 Apr 16. doi: 10.1111/jdv.19117. Epub ahead of print. PMID: 37062048.
* Granieri G, **Michelucci A**, Manzo Margiotta F, Fidanzi C, Salvia G, Bevilacqua M, Dini V, Romanelli M. Biological therapy in pyoderma gangrenosum: the experience of the Department of Dermatology of Pisa. *Abstract*, SAWC Spring National Harbor - 2023, April 26-30.
* **Michelucci A**, Salvia G, Manzo Margiotta F, Granieri G, Fidanzi C, Bevilacqua M, Dini V, Romanelli M. Fluorescence-based evaluation of bacterial load in lower leg wounds: a comparison between compressive multilayer bandage and zinc oxide bandage. *Abstract*, SAWC Spring National Harbor - 2023, April 26-30.
* Romanelli M, Manzo Margiotta F, **Michelucci A**, Granieri G, Janowska A, Dini V. Compression Therapy in Dermatology. Curr Derm Rep (2023). <https://doi.org/10.1007/s13671-023-00388-7>
* Bevilacqua M, Granieri G, Fidanzi C, Salvia G, Margiotta FM, **Michelucci A**, Romanelli M, Dini V. Pyoderma gangrenosum in a patient with Dubowitz syndrome: a new comorbidity? Wounds. 2023 Mar;35(3):E123-E125. doi: 10.25270/wnds/22051. PMID: 37023352.
* **Michelucci A**, Manzo Margiotta F, Granieri G, Morganti R, Romanelli M, Dini V. Advanced wound management approaches in hidradenitis suppurativa postsurgical lesions: the use of an oxygen-enriched oil-based medical device with prolonged release of reactive oxygen species. *Abstract*, 12th EHSF Congress – Firenze, 2023, February 8-10
* **Michelucci A**, Manzo Margiotta F, Granieri G, Romanelli M, Dini V. A non invasive assessment with a fluorescence device for the detection of colonized hidradenitis suppurativa lesions. *Abstract*, 12th EHSF Congress – Firenze, 2023, February 8-10
* Dini V, **Michelucci A**, Manzo Margiotta F, Granieri G, Oranges T, Romanelli M. UHFUS with 70 MHz probe for the early anatomic detection of follicle obstruction in patients affected by hidradenitis suppurativa. *Abstract*, 12th EHSF Congress – Firenze, 2023, February 8-10
* Granieri G, **Michelucci A**, Manzo Margiotta F, Bevilacqua M, Romanelli M, Dini V. A new ultraportable negative pressure wound therapy in the management of hidradenitis suppurativa post surgical lesions: a case report. *Abstract*, 12th EHSF Congress – Firenze, 2023, February 8-10
* Salvia G, **Michelucci A**, Manzo Margiotta F, Bevilacqua M, Mazzatenta C, Romanelli M, Dini V. A patient with hidradenitis suppurativa and psoriasis treated with Brodalumab who developed pyoderma gangrenosum : a paradoxical reaction? *Abstract*, 12th EHSF Congress – Firenze, 2023, February 8-10
* Granieri G, Manzo Margiotta F, **Michelucci A**, Janowska A, Scatena C, Romanelli M, Dini V.In vivo-ex vivo correlation of Hidradenitis Suppurativa anatomical lesions using Ultra-High Frequency Ultrasound and histopathological evaluation. *Abstract*, 12th EHSF Congress – Firenze, 2023, February 8-10
* Efficacy of two different Ixekizumab protocols in the management of recalcitrant Hidradenitis Suppurativa. Manzo Margiotta F, **Michelucci A**, Granieri G, Fidanzi C, Romanelli M, Dini V. *Abstract*, 12th EHSF Congress – Firenze, 2023, February 8-10
* Manzo Margiotta F, **Michelucci A**, Granieri G, Janowska A, Romanelli M, Dini V. Recurrence rates of Hidradenitis Suppurativa lesions explored with pre-surgical mapping with UHFUS. *Abstract*, 12th EHSF Congress – Firenze, 2023, February 8-10
* Salvia G, **Michelucci A**, Granieri G, Manzo Margiotta F, Bevilacqua M, Fidanzi C, Panduri S, Romanelli M, Dini V. An Integrated Systemic and Local Wound Management in Recalcitrant Pyoderma Gangrenosum. Int J Low Extrem Wounds. 2023 Jan 3:15347346221148818. doi: 10.1177/15347346221148818. Epub ahead of print. PMID: 36597572.
* Granieri G, **Michelucci A**, Manzo Margiotta F, Dini V, Romanelli M. Psoriasis and thermal treatments: scientific evidences. La nuova clinica termale, rassegna di idrologia, climatologia medica e medicina termale, n 2-3 2022
* **Michelucci A**, Manzo Margiotta F, Granieri G, Fidanzi C, Salvia G, Bevilacqua M, Dini V, Romanelli M. Valutazione dei fattori di rischio per lo switch terapeutico in pazienti con psoriasi moderata e grave trattati con Secukinumab o Ixekizumab. *Abstract,* 96° Congresso Nazionale SIDeMaST - Milano, 2022, June, 22-25
* Bevilacqua M, Granieri G, Fidanzi C, Manzo Margiotta F, **Michelucci A**, Romanelli M, Dini V. Pioderma gangrenoso in paziente con sindrome di Dubowitz: una nuova comorbidità? *Abstract,* 96° Congresso Nazionale SIDeMaST - Milano, 2022, June, 22-25
* Granieri G, Fidanzi C, Salvia G, Bevilacqua M, **Michelucci A**, Manzo Margiotta F, Dini V, Romanelli M. Nuovo metodo di identificazione della giunzione dermoepidermica: il ruolo dell’ecografia ad altissima risoluzione. *Abstract,* 96° Congresso Nazionale SIDeMaST - Milano, 2022, June, 22-25
* Manni E, Fidanzi C, Granieri G, Bevilacqua M, Salvia G, Manzo Margiotta F, **Michelucci A**, Ortenzi V, Dini V, Romanelli M. Botriomicosi cutanea in paziente con Agammaglobulinemia di Bruton. *Abstract,* 96° Congresso Nazionale SIDeMaST - Milano, 2022, June, 22-25
* Manzo Margiotta F, **Michelucci A**, Fidanzi C, Granieri G, Bevilacqua M, Salvia G, Dini V, Romanelli M. Differenza di efficacia clinica nella risposta di trattamento con anti-interleuchine tra pazienti con psoriasi naive e non naive alla terapia biologica. *Abstract,* 96° Congresso Nazionale SIDeMaST - Milano, 2022, June, 22-25
* Manzo Margiotta F, **Michelucci A**, Panduri S, Tonini A, Davini G, Romanelli M, Morganti R, Dini V. Family history of psoriasis: a novel protective factor for therapy switch in patients treated with Secukinumab or Ixekizumab. J Eur Acad Dermatol Venereol. 2022 Jun;36(6):e454-e456. doi: 10.1111/jdv.17944. Epub 2022 Jan 29. PMID: 35048437.
* **Michelucci A**, Manzo Margiotta F, Panduri S, Tonini A, Romanelli M, Morganti R, Janowska A, Dini V. A real-life experience as a proof of Guselkumab effectiveness and safety in patients with moderate to severe psoriasis. Dermatol Ther. 2022 Apr;35(4):e15339. doi: 10.1111/dth.15339. Epub 2022 Feb 8. PMID: 35088508.

**PRESENTAZIONI ORALI**

* Inibizione di IL-17A e IL-17F per il trattamento di un caso recalcitrante di sindrome PASH. **Michelucci A.** V Congresso Regionale Toscano SIDeMaST - ADOI - Pisa, 14 Dicembre 2024.
* Patient Profile Detection. **Michelucci A**. Future IDays: Diamo forma a nuove risposte per le sfide in immunodermatologia - Torino, 24-25 Ottobre 2024.
* Moisture-Associated Skin Damage (MASD) in hidradenitis suppurativa: Mechanisms, clinical implications and targeted management strategies. **Michelucci A**. 33° European Academy of Dermatology and Venereology (EADV) Congress– Amsterdam, 25-28 Settembre 2024.
* Giornate Maremmane XIX edizione, Experts Dermatologists Discussion II- Grosseto, 21 Settembre 2024.
* Non-invasive diagnostics in wound assessment. **Michelucci A.** 1st Global Wound Hygiene Advanced Masterclass: Protocol & Practice in Management of Hard to Heal Wounds”- Pisa, 9-11 Settembre 2024.
* Hidradenitis suppurativa**. Michelucci A.** 1st Global Wound Hygiene Advanced Masterclass: Protocol & Practice in Management of Hard to Heal Wounds”- Pisa, 9-11 Settembre 2024.
* Epidemiologia, patogenesi e Score dell’HS. **Michelucci A**. RHiSe UP - Raise HS awareness to Unlock Patient journey – Pisa, 25 Giugno 2024.
* HS: IL RUOLO DEL WOUND CARE. **Michelucci A.** XIV International Dermatologic Galilei Symposium- "Eppur si Muove"- Landscape of Hidradenitis Suppurativa. Pisa,14-16 Giugno 2024.
* Eruzioni Eczematose Paradosse in pazienti con psoriasi trattati con terapia biologica. **Michelucci A**. 98° Congresso Nazionale SIDeMaST – Giardini di Naxos, 28-31 Maggio 2024.
* Terapia a Pressione Negativa. **Michelucci A**. 98° Congresso Nazionale SIDeMaST – Giardini di Naxos, 28-31 Maggio 2024.
* Aspetti clinici delle ulcere croniche. **Michelucci A**. Le 50 sfumature nel Wound Care – Carrara, 25 Maggio 2024.
* Optimizing outcomes in Hidradenitis Suppurativa surgical treatment: a comprehensive analysis of postoperative complications and quality of life impact**. Michelucci A**. European Wound Management Association (EWMA) Conference – Londra, 1-5 Maggio 2024.
* Wound Area Severity Index (WASI): a novel tool for predicting healing times in Hidradenitis Suppurativa post-surgical wounds. **Michelucci A**. European Wound Management Association (EWMA) Conference – Londra, 1-5 Maggio 2024.
* Risankizumab in the management of refractory Pyoderma Gangrenosum: a combined approach of systemic therapy and local wound management. **Michelucci A**. European Wound Management Association (EWMA) Conference – Londra, 1-5 Maggio 2024.
* L’utilizzo dei farmaci biologici nel Wound Care. **Michelucci A.** V Edizione, La gestione complessa delle ulcere cutanee tra ospedale e territorio – Pisa, 1 Marzo 2024.
* Optimizing outcomes in hidradenitis suppurativa surgical treatment: a comprehensive analysis of postoperative complications and quality of life impact. **Michelucci A.** 13th CONFERENCE of the European Hidradenitis Suppurativa Foundation Suppurative Hidradenitis: Imagining Future Transitions – Lione, 7-9 Febbraio 2024.
* Wound Area Severity Index (WASI): a novel tool for predicting healing times in hidradenitis suppurativa post-surgical wounds. **Michelucci A.** 13th CONFERENCE of the European Hidradenitis Suppurativa Foundation Suppurative Hidradenitis: Imagining Future Transitions – Lione, 7-9 Febbraio 2024.
* Idrosadenite del cuoio capelluto in terapia con anti IL-17. **Michelucci A**. IV Congresso Regionale Toscano SIDeMaST-ADOI - Firenze, 16 Dicembre 2023.
* Bimekizumab, a new way to treat erythrodermic psoriasis: a case report. **Michelucci A.** Convegno Nazionale BiGeneration - Future trends in psoriasis treatment – Roma, 29-30 Novembre 2023
* Psiche e patologie dermatologiche. **Michelucci A.** Giornate Pisane di Medicina Del Lavoro – Pisa, 6 Novembre 2023.
* Hidradenitis suppurativa topical management: new insight in HS-TIME. **Michelucci A,** Dini V, Manzo Margiotta F, Granieri G, Romanelli M. EHSF Session. 32° European Academy of Dermatology and Venereology (EADV) Congress – Berlino, 11-14 Ottobre 2023.
* Anti IL-23 monoclonal antibodies: a new therapeutic approach for the treatment of recalcitrant Pyoderma Gangrenosum. **Michelucci A.** 25 th World Congress of Dermatology (WCD) – Singapore, 3-8 Luglio 2023.
* Gli ostacoli locali alla guarigione: dal biofilm all’eccesso di infiammazione. **Michelucci A**. Il paziente con lesioni cutanee e un approccio di cura innovativo – Firenze, 1 Aprile 2023
* YELLOW: le ulcere a fondo giallo non sono tutte uguali. **Michelucci A**. IV Edizione, La gestione complessa delle ulcere cutanee tra ospedale e territorio – Pisa, 3 Marzo 2023.
* Advanced wound management approaches in hidradenitis suppurativa postsurgical lesions: the use of an oxygen-enriched oil-based medical device with prolonged release of reactive oxygen species. **Michelucci A**, Manzo Margiotta F, Granieri G, Morganti R, Romanelli M, Dini V. 12th CONFERENCE of the European Hidradenitis Suppurativa Foundation Facing HS according to the Renaissance style– Firenze, 8-10 Febbraio 2023.
* Approccio chirurgico e gestione delle ferite postchirugiche in pazienti affetti da idrosadenite suppurativa, **Michelucci A**. III Congresso Regionale Toscana SIDeMaST-ADOI – Siena, 26 Novembre 2022.
* Valutazione dei fattori di rischio per lo switch terapeutico in pazienti con psoriasi moderata e grave trattati con Secukinumab o Ixekizumab, **Michelucci A**. 96° Congresso Nazionale SIDeMaST - Milano, 22-25 Giugno 2022.
* Standardized local management of malignant fungating wounds:the PEBO approach, **Michelucci A**. EWMA/Journées Cicatrisation Conference - Parigi, 23-25 Maggio 2022.
* Utilizzo di matrice oleica a rilascio di specie reattive di ossigeno nelle ulcere postchirurgiche da idrosadenite, **Michelucci A**. XVI congresso nazionale AIUC - Roma, 17-20 Novembre 2021.

**ATTIVITA’ DI RICERCA CLINICA**

CLINICAL TRIALS

* A Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis (G- PLUS); CNTO1959PSO3013; JANSSEN CILAG; Sub-investigator
* Psoriasis Study of Health Outcomes (PSoHO) – an International Observational Study of 3-Year Health Outcomes in the Biologic Treatment of Moderate – to - Severe Plaque Psoriasis; I1F-MC- B007; Lilly; Sub-investigator
* A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics (PSOLAR); C0168Z03; JANSSEN CILAG; Sub-investigator
* Observational study on Guselkumab: effectiveness and impact on quality of lIfe in naïve or bio experienced patients with Regional (facial and genital) psoriasis (GULLIVER) ;CNTO1959PSO4013; JANSSEN CILAG; Sub-investigator
* Long term observational, prospective study in a real life setting data on the retention, effectiveness, safety, treatment pattern, quality of life, and efficacy of secukinumab in audit patients with moderate to severe plaque psoriasis (SERENA); CAIN457A3403; NOVARTIS; Sub- Investigator
* Multi-country prospective observationaL, cohort study of patients with moderate to severe chronic plaque psoriasis (VALUE); P19-377; ABBVIE, Sub-Investigator
* An efficacy adn safety comparison of brodalumab versus guselkumab in adult subjects with moderate to severe plaque psoriasis and inadequate response to ustekinumab (COBRA); LP0160-1510; LEO PHARMA; Sub-Investigator
* Evaluation of the performance and safety of a light kaolin plus silver sulfadiazine powder spray dressing on skin lesions with exudative component. A multicenter, single arm, open label study. Protocollo: PSC-DS Silk 19. Sponsor: SOFAR. Sub-Investigator
* L.U.C.E. (Leg Ulcers standard of Care Enhancement) Studio multicentrico, randomizzato controllato, prospettico sulla velocità di guarigione, qualità della vita e costo/efficacia del trattamento con il dispositivo EmoLED vs trattamento standard delle ulcere degli arti inferiori; EmoLED\_003; EMOLED; Sub-investigator
* A 24-week, randomised, assessor-blinded, active-controlled, parallel-group, phase 3, 2-arm trial to compare the efficacy and safety of delgocitinib cream 20 mg/g twice-daily with alitretinoin capsules once-daily in adult participants with severe chronic hand eczema; LP0133-1528; LEO PHARMA; Sub-Investigator
* A Monocentric, Controlled, Randomized,Observer-Blinded Study of the Safety and Effectiveness of Foliage Lips Volume versus Belotero® Balance, for Lip and Perioral Enhancement; PHT-2021/02; PHITOGEN; Sub-Investigator
* A Monocentric, Prospective, Randomized, Observer-Blinded, Controlled withinsubject study of the Effectiveness and Safety of Foliage Intense 1x1 mL versus Belotero® Intense, for the correction of moderate and severe nasolabial folds; PHT-2021/01; PHITOGEN; Sub-Investigator
* A prospective, controlled, randomized, double-blind, premarket multicenter study of the performance of the hm242-solution vs comparator in patients under the condition of venous leg ulcer; OPM-G-H-2003; B.BRAUN, Sub-Investigator
* A multicenter, open label, uncontrolled study fot the evaluation of efficacy and safety by clinical parameters of relizema ecofoam in adult atopic and contact dermatitis; ReGl/20/Rec-Der/001; Relife, Sub-Investigator
* PSO FOOD - L'educazione alimentare cambia pelle: Valutazione di un programma di coaching nutrizionale virtuale nei pazienti con psoriasi sovrappeso od obesi; Sub-Investigator
* Psychological wellBeing of moderate-to-severe pLaque psoriasis patients treated with tildrakizUmab in clinical practicE in Italy. BLUE Study; M-14745-49; Almirall, Sub-Investigator
* A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis; M16-045; AbbVie, Sub-Investigator
* A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects with Moderate to Severe Atopic Dermatitis (Level-Up); M23-696; AbbVie, Sub-investigator
* A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects with Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy; M23-698; AbbVie, Sub-Investigator
* A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis. Protocollo: M16-047. Sponsor: AbbVie. Sub-Investigator
* Selective Treatment of Oral Povorcitinib in Hidradenitis Suppurativa Study 2 (STOP-HS2). A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa; INCB 54707-302; Incyte, Sub-Investgator
* A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate the efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum; IFX-1-P3.4; InflaRx, Sub-Investigator
* Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1; 1368-0098; Boehringer-Ingelhaim, Sub-Investigator
* Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS); 1368-0130; Boehringer-Ingelhaim, Sub-Investigator
* A multicenter, randomized, parallel-group, double-blind, active-controlled study to evaluate the efficacy and safety of bimekizumab compared to ustekinumab in children and adolescents from 6 years to less than 18 years of age with moderate to severe plaque psoriasis. Protocollo: PS0021. Sponsor: UCB Biopharma. Sub-Investigator
* A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis. Protocollo: M-17923-34. Sponsor: Almirall. Sub-Investigator
* A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy. Protocollo: M24-541. Sponsor: AbbVie. Sub-Investigator
* A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa. Protocollo: M1095-HS-301. Sponsor: MoonLake Immunotherapeutics. Sub-Investigator
* Observational study of treatment history, quality of life, treatment satisfaction, and disease symptom severity in adult patients with moderate to severe plaque psoriasis treated with bimekizumab in routine clinical practice (ELEVATE). Protocollo: PS0035. Sponsor: UCB Biopharma. Sub-Investigator
* A Phase 3, Multicentre, Randomised, Double-blind, Vehicle-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Tirbanibulin 10 mg/g Ointment Applied to a Treatment Field Larger Than 25 cm2 and up to 100 cm2 in Adult Patients With Actinic Keratosis. Protocollo: M14867-33. Sponsor: Almirall. Sub-Investigator
* A multi-centre, randomised, placebo-controlled, doubleblind, parallel-group trial to evaluate safety and efficacy of spesolimab (BI 655130) in adult patients with ulcerative pyoderma gangrenosum (PG) who require systemic therapy. Protocollo: 1368-0140. Sponsor: Boehringer-Ingelheim. Sub-Investigator
* A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis. Protocollo: EFC17560. Sponsor: Sanofi. Sub-Investigator
* A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis on background topical corticosteroids. Protocollo: EFC17561. Sponsor: Sanofi. Sub-Investigator
* A Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group 48-week extension study to evaluate the treatment response and safety of two amlitelimab dose regimens administered as monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis. Protocollo: EFC17600. Sponsor: Sanofi. Sub-Investigator
* A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis; INCB18424-320; Incyte, Sub-Investigator

**ESPERIENZA LAVORATIVA**

* **9-11 Settembre 2024** - Speaker e Tutor di Workshop, "1st Global Wound Hygiene Advanced Masterclass", Pisa, Italia.
* **19-25 Giugno 2024** - Docente nel corso di Dermatologia e Venereologia DEL “CdL in Odontoiatria e Protesi Dentaria”, Università di Pisa, Italia.
* **18-25 Giugno 2024** - Docente nel corso di Dermatologia e Venereologia DEL “CdL in Igiene Dentale”, Università di Pisa, Italia.
* **Maggio - Dicembre 2024** - Docente nel "Master in Dermatologia Cosmetologica Rigenerativa ed Estetica II livello", Pisa, Italia.
* **Aprile – Dicembre 2024** - Docente nel "Master Universitario di primo livello in Wound Care", Pisa, Italia.
* **Dal 2022 - in corso** - Medico volontario, Lega Italiana per la Lotta contro i Tumori (LILT), Massa, Italia.
* **Giugno - Dicembre 2021** - Medico per l'emergenza Covid-19, Synergie Italia.
* **Novembre 2020 – Gennaio 2021** - Attività di contact tracing per la Protezione Civile Italiana, Azienda USL Toscana Nord Ovest, Carrara, Italia.

**COMPETENZE LINGUISTICHE**

* **Italiano:** Madrelingua
* **Inglese:** B2 (Ascolto, Lettura, Scrittura, Produzione e Interazione Orale)
* **Francese:** A2 (Ascolto, Lettura, Scrittura, Produzione e Interazione Orale)

**COMPETENZE INFORMATICHE**

Microsoft Office / Microsoft Excel / Microsoft Word / Microsoft Powerpoint / SISPC

Il/La sottoscritto/a, sotto la propria personale responsabilità e consapevole delle sanzioni previste dall’art.76 del DPR n.445 del 28/12/2000, per le ipotesi di falsità in atti e dichiarazioni mendaci, dichiara che quanto sopra riportato corrisponde al vero. Dichiara, altresì, di essere informato ai sensi e per gli effetti di cui al D.Lgs n.196/2003, codice in materia di protezione dei dati personali del 30/06/2003, e dell’Art. 13 del Regolamento UE 679/2016, che i dati personali raccolti saranno trattati, anche con strumenti informatici,esclusivamente nell'ambito del procedimento ECM per il quale la presente dichiarazione viene resa. Autorizzo il trattamento dei miei dati personali ai sensi del D.Lgs sopra menzionato;"

**29/01/2025**